Amid the trade tensions between the US and Europe, there is a often overlooked policy lever worth noting. The US government can activate the FDA's "Critical Drug Shortage" emergency provisions to authorize domestic compounding pharmacies to produce prescription drugs like insulin and Ozempic, directly impacting the profit margins of Denmark's pharmaceutical industry. This move may seem aggressive, but it is supported by clear legal precedents. For crypto market participants monitoring global economic trends, such policy shifts often trigger volatility in commodities and healthcare sectors, subsequently influencing institutional investment strategies.